3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
7
Colonic Neoplasms
6
Recurrence
4
Prostatic Neoplasms
4
Neoplasms
4
Polycythemia Vera
3
Venous Thromboembolism
2
Thrombocythemia, Essential
2
Rectal Neoplasms
2
Myocardial Infarction
2
Esophageal Neoplasms
2
Cardiovascular Diseases
2
Adenoma
2
Vascular Diseases
1
Thrombosis
1
Thrombocytopenia
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precancerous Conditions
1
Pathologic Processes
1
Node Positive HER2 Negative Breast Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Myocardial Ischemia
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lynch syndrome I (site-specific colonic cancer)
1
Lymphoma, Follicular
1
Liver Cirrhosis
1
Ischemic Stroke
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Aspirin
×
Clear all
NCT07529262
2026-04-14
AspiRe HCC
Curtin University
Phase 3
Not yet recruiting
890 enrolled